Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomised, Double-Blind, Fixed-Dose, Bifeprunox Study Combining a 12-Week Placebo-Controlled, Quetiapine-Referenced Phase With a 12-Month Quetiapine-Controlled Phase in Patients With Schizophrenia

NCT00704509 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT00704509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00704509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomised, Double-Blind, Fixed-Dose, Bifeprunox Study Combining a 12-Week Placebo-Controlled, Quetiapine-Referenced Phase With a 12-Month Quetiapine-Controlled Phase in Patients With Schizophrenia
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2008
Completion date
November 30, 2009
Enrollment
346 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia